A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).
Tolaney S, Duda D, Boucher Y, Goel S, Martin J, Ancukiewicz M, Potler H, Incio J, Ligibel J, Isakoff S, Fukumura D, Winer E, Krop I, Jain R. A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 1026-1026. DOI: 10.1200/jco.2012.30.15_suppl.1026.Peer-Reviewed Original ResearchTN breast cancerBreast cancerInterstitial fluid pressureMiller-PayneTN tumorsHER2-negative operable breast cancerMean interstitial fluid pressureHormone receptorsMP responseAddition of BevAxillary LN involvementDose-dense doxorubicinTriple-negative cohortOperable breast cancerPhase II studyPredictors of responseMean vascular densityPreoperative bevacizumabLN involvementII studyOverall cohortPathologic responseBiomarker predictorsNegative cohortPharmacodynamic effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply